These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 322921)

  • 21. Guanabenz and methyldopa on hypertension and cardiac performance.
    Walker BR; Shah RS; Ramanathan KB; Vanov SK; Helfant RH
    Clin Pharmacol Ther; 1977 Dec; 22(6):868-74. PubMed ID: 336257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of hypertension in pregnancy with methyldopa: blood pressure control and side effects.
    Redman CW; Beilin LJ; Bonnar J
    Br J Obstet Gynaecol; 1977 Jun; 84(6):419-26. PubMed ID: 329859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antagonism of conditioned salivation in conscious dogs by antihypertensive drugs.
    Sweet CS; Gaul SL
    Can J Physiol Pharmacol; 1977 Aug; 55(4):968-71. PubMed ID: 902171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemodynamic changes in long-term -methyldopa therapy of essential hypertension.
    Lund-Johansen P
    Acta Med Scand; 1972 Sep; 192(3):221-6. PubMed ID: 5055268
    [No Abstract]   [Full Text] [Related]  

  • 25. A comparison between spironolactone and hydrochlorothiazide with and without alpha-methyldopa in the treatment of hypertension.
    Walter NM; Suthers MB; Friedman A; Johnston CI
    Med J Aust; 1978 May; 1(9):509-12. PubMed ID: 353458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evaluation by practicing physicians of the antihypertensive efficacy of debrisoquin, methyldopa and propranolol].
    Avigdor L; Waeber B; Brunner HR
    Schweiz Med Wochenschr; 1983 Mar; 113(9):331-8. PubMed ID: 6342133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Dose-effect comparison of antihypertensive combinations with and without alpha-methyldopa].
    Krämer KD; Ghabussi P; Lehmann HU; Hochrein H
    MMW Munch Med Wochenschr; 1975 Apr; 117(14):579-82. PubMed ID: 806789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; Bartholini G; Constantinidis J; Eisenring JJ; Geissbühler F; Yanniotis G; de Ajuriaguerra J
    Schweiz Med Wochenschr; 1973 Oct; 103(42):1466-74. PubMed ID: 4750149
    [No Abstract]   [Full Text] [Related]  

  • 29. The effect of some decarboxylase inhibitors on striatal tyramines in the mouse.
    Juorio AV
    Neuropharmacology; 1983 Jan; 22(1):71-3. PubMed ID: 6843786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
    Tayarani-Binazir KA; Jackson MJ; Fisher R; Zoubiane G; Rose S; Jenner P
    Eur J Pharmacol; 2010 Jun; 635(1-3):109-16. PubMed ID: 20303948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of indoramin and methyldopa in hypertension.
    Rosendorff C
    S Afr Med J; 1976 May; 50(20):764-8. PubMed ID: 779054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Haemodynamic changes in long-term therapy of essential hypertension: a comparative study of diuretics, alpha-methyldopa and clonidine.
    Lung-Johansen P
    Clin Sci Mol Med Suppl; 1973 Aug; 45 Suppl 1():199s-203. PubMed ID: 4593565
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparison of prazosin and methyldopa in mild to moderate hypertension, a multicenter cooperative study.
    Bradley WF; Hoffman FG; Hutchison JC; Kalams Z; Waldron SL
    Curr Ther Res Clin Exp; 1977 Jan; 21(1):28-35. PubMed ID: 401709
    [No Abstract]   [Full Text] [Related]  

  • 35. The addition of Visken to methyldopa therapy in hypertension: a multicentre study.
    Murphy JE
    J Int Med Res; 1976; 4(2):128-31. PubMed ID: 1026542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Guanabenz versus methyldopa in the therapy of mild-to-moderate hypertension.
    Rosendorff C
    S Afr Med J; 1982 Sep; 62(13):435-7. PubMed ID: 7051365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor].
    Meco G; Casacchia M; Zamponi A; Agnoli A
    Acta Neurol (Napoli); 1976; 31(4):479-48. PubMed ID: 1037427
    [No Abstract]   [Full Text] [Related]  

  • 38. [Effect of hypotensive substances (hypothiazide, guanetidine, alpha-methyldopa) on basic hemodynamic indices].
    Glezer GA
    Kardiologiia; 1968 Aug; 8(8):113-8. PubMed ID: 5727457
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparison of prazosin and methyldopa in essential hypertension: results of a randomized, double-blind, parallel trial.
    Whelton PK; Russell RP; Sova-Schulz K; Wyndham R; Walker WG
    J Cardiovasc Pharmacol; 1979; 1(6 Suppl):S28-37. PubMed ID: 94637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparative study of methyldopa and labetalol in the treatment of hypertension.
    Sanders GL; Davies DM; Gales GM; Rao JG; Rawlins MD; Routledge PA
    Br J Clin Pharmacol; 1979; 8(Suppl 2):149S-151S. PubMed ID: 393286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.